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Abstract
The objective of this investigation was to develop and evaluate a nano-microbicide containing a 
combination of cellulose acetate phthalate (HIV-1 entry inhibitor) and efavirenz (anti-HIV agent) 
for HIV prophylaxis. Cellulose acetate phthalate-efavirenz combination nanoparticles (CAP-EFV-
NPs) were fabricated by the nanoprecipitation method and were characterized for particle size, 
zeta potential and encapsulation efficiency of efavirenz. CAP-EFV-NPs were incorporated into a 
thermosensitive gel (CAP-EFV-NP-Gel). CAP-EFV-NPs, CAP-EFV-NP-Gel and efavirenz 
solution were evaluated for cytotoxicity to HeLa cells and for in vitro short-term (1-day) and long-
term (3-day) prophylaxis against HIV-1 infection in TZM-bl cells. CAP-EFV-NPs had size < 100 
nm, negative surface charge and encapsulation efficiency of efavirenz was > 98%. CAP-EFV-NPs 
and CAP-EFV-NP-Gel were significantly less toxic (P < 0 01) to HeLa cells as compared to 
efavirenz solution. CAP-EFV-NPs showed significantly higher prophylactic activity (P < 0 01) 
against HIV-1 infection to TZM-bl cells as compared to efavirenz solution and blank CAP 
nanoparticles. CAP-EFV-NP-Gel can be a promising nano-microbicide for long-term HIV 
prophylaxis.
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INTRODUCTION
HIV infection is a serious global issue. At the moment, more than 34 million people are 
infected with HIV worldwide and 2.5 million people were newly infected with HIV in 
2011.1 Prevention as well as treatment of HIV infection has become a world-wide priority in 
order to reach the international goal of reducing HIV-1 infection by 50% in 2015.2 As sexual 
transmission is the most common mode of HIV infection, researchers have focused on 
developing modalities that can inhibit HIV-1 at the site of infection and prevent acquisition 
of HIV. Physical barriers such as condoms and male circumcision are currently used for HIV 
prophylaxis and have shown only moderate success.3 Hence, ‘use of topical (vaginal or 
rectal) microbicides’ is considered to be an important strategy for HIV prophylaxis. Topical 
microbicides are able to inactivate HIV-1, block HIV-1 attachment, and/or disrupt 
intracellular HIV replication.4,5
Macromolecular HIV-1 entry inhibitors like cellulose sulfate, PRO-2000 and carrageenan 
sulfate were evaluated as vaginal microbicides but they failed to show any significant 
protective effect in clinical trials.6 Hence, antiretroviral agents such as tenofovir are also 
being evaluated as a vaginal microbicide. In CAPRISA 004 trial, pre-and post-coital 
application of 1% tenofovir gel showed some degree of success in preventing acquisition of 
HIV infection.7 However, coitus-independent, once daily application of 1% tenofovir gel did 
not show any efficacy in VOICE trial.8 These results suggest that development of 
combination vaginal microbicides with coitus independent activity is of great importance. 
Recently, a combination of carrageenan, zinc acetate and MIV-150 was found to give one 
day protection from HIV infection in macaques.9 At the moment, a vaginal ring containing a 
combination of dapivirine (a non-nucleoside reverse transcriptase inhibitor or NNRTI) and 
maraviroc (an entry inhibitor that blocks CCR5 receptor) is being evaluated in clinical trials.
10
 Thus, combination of an entry inhibitor and a NNRTI may provide needed HIV 
prophylaxis.
Cellulose acetate phthalate (CAP) is a low-cost pharmaceutical excipient that is widely used 
for the enteric coating of pharmaceutical formulations.11 CAP is pH sensitive polymer that 
dissolves at pH higher than 6.2.12 Interestingly, CAP was found to be active against viruses 
such as HIV-1, HSV-1 and HSV-2 indicating its potential as a topical microbicide.13 CAP 
acts as a HIV-1 entry inhibitor (for R4 and R5 tropic viruses) by binding to gp 120 and by 
formation of gp 41 six-helix bundles.14,15 CAP can also result in virus disintegration and 
stripping of envelope glycoproteins causing loss of viral infectivity.14–16 Due to pH sensitive 
nature, CAP can maintain its integrity in the acidic environment of vagina. CAP was found 
to be active against HIV-1 in soluble as well as insoluble form indicating that CAP can 
prevent HIV infection in vaginal lumen (cervicovaginal mucus) as well as vaginal mucosa.16 
Vaginal application of a gel containing micronized CAP (13% w/v) did not alter vaginal pH, 
vaginal microflora or integrity of vaginal epithelium in macaques.17–19 CAP gel successfully 
prevented macaques from SHIV infection even after repeated viral exposure.17–19 In a recent 
phase 1 clinical trial, CAP gel was found to cause unacceptable vulvo-vaginal side effects 
due to very high osmolarity of gel.20 Thus, there is a need for an alternative formulation 
approach for CAP and continued evaluation of the prophylactic properties of CAP alone or 
in combination with other anti-retroviral drugs.
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Nanotechnology has garnered considerable interest in the field of HIV prophylaxis. Various 
types of nanocarriers such as dendrimers, liposomes, polymeric nanoparticles and 
nanosuspensions are being evaluated for this purpose.21,22 Currently, a gel containing 
dendrimers (VivaGel®, Starpharma, Australia) is being evaluated in the clinical trials for 
prophylactic activity against HIV and other sexually transmitted diseases.23,24 In view of 
this, formulating CAP as nanoparticles is a promising approach. Until today, there are no 
reports on fabrication of CAP nanoparticles for HIV prophylaxis. In the present 
investigation, we developed a vaginal nano-microbicide containing a combination of a 
HIV-1 entry inhibitor, CAP and a NNRTI, efavirenz. The objective of this investigation was 
to establish a proof-of-concept for use of CAP as a microbicide as well as a (nano)carrier for 
delivering efavirenz (EFV). The CAP nanoparticles and CAP-EFV nanoparticles (CAP-
EFV-NPs) were evaluated for cytotoxicity and antiviral efficacy. Finally, CAP-EFV-NPs 
were incorporated into a thermosensitive gel to enable their effective vaginal delivery.
MATERIALS AND METHODS
Materials
Cellulose acetate phthalate (CAP), polysorbate 80 (Tween 80), polysorbate 20 (Tween 20), 
polyoxyethylene-40-stearate (Myrj 52) were purchased from Sigma Chemicals (St. Louis, 
MO). Efavirenz (EFV) was purchased from Sequoia Research Ltd. (Pangbourne, UK). 
Potassium dihydrogen phosphate (HPLC grade), acetonitrile (HPLC grade), dimethyl 
sulfoxide (DMSO, AR Grade), acetone (AR grade), citric acid (AR grade), trisodium citrate 
(AR grade) and Rhodamine 6G were purchased from Fischer Scientific Ltd (Pittsburg, PA, 
USA). Pluronic F127, Pluronic F68, Solutol HS 15 and Kolliphor TPGS (BASF Corp., 
Edison, NJ, USA) were received as gift samples. Ultrapure water was used for all the 
experiments.
Cell Culture
Human cervical (HeLa) cells were purchased from American Tissue Culture Collection 
(ATCC, Manassas, VA). TZM-bl cells were procured through NIH AIDS Research and 
Reference Reagent Program. HeLa and TZM-bl cells were maintained in Dulbecco’s 
Modified Eagle Media (DMEM, MediaTech Inc., Manassas, VA) supplemented with 10% 
fetal bovine serum (FBS, Hyclone Inc., Utah), 4 mM L-glutamine, 100 U/ml penicillin and 
100μg/ml streptomycin (MP Biomedical Inc., Solon, OH) and maintained in a logarithmic 
growth phase. All cells were grown at 37°C and 5% CO2.
Preparation of Blank CAP Nanoparticles
Blank CAP nanoparticles were prepared using a nanoprecipitation method. Various 
stabilizers such as Tween 80, Tween 20, Myrj 52, Solutol HS 15, Kolliphor TPGS, Pluronic 
F68 and Pluronic F127 were evaluated for the fabrication of blank CAP nanoparticles. 
Briefly, CAP (50 mg) was dissolved in 10 ml of acetone (organic phase) by heating at 40°C 
in an incubating shaker bath. A selected stabilizer (200 mg) was dissolved in 10 ml of ultra-
pure water (aqueous phase) by heating at 40°C in an incubating shaker bath. Aqueous phase 
(10 ml) was transferred to a 50 ml beaker and the beaker was kept on a magnetic stirrer. The 
aqueous phase was stirred at 700 rpm, the organic phase was added drop-wise under stirring 
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to an aqueous phase (10 ml) and stirring was continued for 3 h to remove acetone. The 
particle size of the resulting CAP nanoparticle dispersion was measured. All experiments 
were carried out in triplicate.
In Vitro Cytotoxicity of CAP Nanoparticles
In vitro cytotoxicity of CAP nanoparticles was evaluated in HeLa cells. Briefly, cells were 
seeded in 12 well plates at a density of 1 × 106 cells/well in triplicate and allowed to attach 
to wells overnight. CAP nanoparticles were added to obtain a CAP concentration of 
500μg/ml, 250μg/ml, 100μg/ml, 50μg/ml, and 5μg/ml in each well. Cell viability was 
assessed after 24 and 48 h as per MTT method described in our earlier paper.25 The 
absorbance obtained for CAP nanoparticles was compared to control cells (no treatment) to 
calculate% cell viability.
Preparation of EFV Loaded CAP Nanoparticles
Briefly, CAP (50 mg), EFV (5 mg) were dissolved in 10 ml of acetone (organic phase) by 
heating at 40°C in an incubating shaker bath. Pluronic F127 (200 mg) was dissolved in 10 
ml of ultra-pure water (aqueous phase) by heating at 40°C in an incubating shaker bath. The 
rest of the procedure was same as described for the blank CAP nanoparticles. The resulting 
CAP nanoparticle dispersion containing EFV (CAP-EFV-NPs) was used for further studies. 
Particle size, polydispersity index, and surface charge of resulting CAP-EFV-NPs were 
measured using dynamic light scattering (ZetaPlus instrument, Brookhaven Instruments 
Corp, NY, USA) as previously described.26 All experiments were carried out in triplicate. 
CAP-EFV-NPs were filtered through a 0.22μm filter and used for further studies. All the 
experiments were carried out in triplicate.
For fabrication of fluorescent CAP nanoparticles, EFV was replaced with Rhodamine 6G (1 
mg) and nanoparticles were prepared as described above.
Entrapment Efficiency
CAP-EFV NPs (0.4 ml) were transferred to a centrifugal filter (Amicon Ultra, Sigma–
Aldrich, MO, USA). The nanoparticle dispersion was centrifuged at 14000 rpm (Eppendorf 
centrifuge 5417R) and at 4°C for 20 min to obtain a filtrate.
The entrapment efficiency was calculated by the following equation:
%EE = [(Minitial − Mfree)/Minitial] × 100
where ‘Minitial’ is the amount of EFV/ml of nanoparticle dispersion and Mfree is amount of 
EFV/ml of filtrate obtained by centrifugation of nanoparticles. All experiments were 
performed in triplicate. The amount of the EFV in the nanoparticles and filtrate was 
analyzed by using a reverse phase-HPLC method described in our earlier paper.26
High-Pressure Liquid Chromatography (HPLC)
The amount of the EFV in the nanoparticles and filtrate was analyzed by using a reverse 
phase-HPLC method described in our earlier paper.26 The HPLC apparatus consisted of a 
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pump (LC-10ATvp), system controller (SIL-10ADvp), degasser unit (DGU-14A), 
refrigerated auto-sampler (SIL-10ADvp), a UV-Vis detector (SPD-10ADvp) and a column 
heater (Shimadzu Corporation, Columbia, MD). Samples were run through a C18 pre-
column and a Gemini C18 reverse-phase [150 × 4 5 mm (I.D.)] with 5 μm particle size 
packing (Phenomenex, Torrance, CA). The mobile phase consisted of acetonitrile and 25 
mM KH2PO4 solution (55:45). For HPLC analysis, the flow rate of the mobile phase was at 
0.9 ml/min, column oven was set at 35°C, injection volume was 20 μl and detector was set at 
212 nm. The retention time for EFV was 10.4 min. For standard curve, EFV stock solution 
(1 mg/ml) was prepared in acetonitrile. The stock solutions were diluted with acetonitrile to 
obtain solutions of various concentrations. Standard curve was obtained by injecting 0.1–10 
μg/ml of EFV. Limit of detection for EFV was 50 ng/ml. All the experiments were 
performed in triplicate. The inter-day and intra-day variability for the standard curve was 
always < 10%.
Imaging of CAP-EFV Nanoparticles by SEM
About 30 μl of CAP-EFV NPs were placed onto a conductive tape (PELCO Tabs, 12 mm 
OD, TED PELLA, Inc, Redding, CA) mounted on a aluminum stub. The NP samples were 
air-dried for > 24 h and sputter-coated with palladium under an argon gas atmosphere using 
a Denton Desk V HP TSC Sputter Coater (Denton Vacuum, LLC-USA, Moorestown, NJ). 
The coated the NPs were examined using a Hitachi S4700 field-emission Scanning Electron 
Microscope (SEM).
Development of a Thermosensitive Vaginal Gel Containing CAP-EFV-NPs
A thermosensitive vaginal gel containing CAP-EFV-NPs was developed as per our earlier 
publication with suitable modifications.26 Briefly, CAP-EFV-NPs were prepared as 
described earlier and the pH was adjusted to 4.5 using a mixture of citric acid and sodium 
citrate. Glycerol (0.225 gm) was added to CAP-EFV-NPs (10 ml) to adjust the osmolarity of 
nanoparticles. CAP-EFV-NPs were transferred to a screw-capped bottle and Pluronic F127 
(2 gm) and Pluronic F68 (100 mg) were added to CAP-EFV-NPs with intermittent stirring. 
The screw-capped bottle containing CAP-EFV-NPs and Pluronics was stored overnight in 
the refrigerator to dissolve Pluronics. On the next day, the dispersions were gently stirred to 
obtain a homogenous translucent solution. The solution was observed for signs of 
nanoparticle aggregation and/or phase separation. Thermosensitivity of the gel was 
confirmed by incubating the gel in the water bath maintained at 37°C.
Characterization of Transfer of Fluorescent CAP Nanoparticles from Thermosensitive Gel 
Using Transwell® Permeable Supports
HeLa cells were plated at 0 5 × 106 cells/ml on Poly-D Lysine pre-coated 12 mm BD 
BioCoat coverslips (BD Bio-sciences, San Jose, CA). Cells were cultured overnight in 
DMEM plus 10% fetal calf serum at 37°C, 5% CO2. Thermosensitive gel (100 μl) 
containing Rhodamine 6G labeled fluorescent CAP nanoparticles was placed on 0.2 μm 
Transwell® permeable supports (Corning Inc. Life Sci., MA, USA) at 37°C for 10 min to 
allow solidification. Transwells® were placed above HeLa cells for 30 min, 2 h, 24 h, 48 h, 
96 h. At each time point, Transwells® were removed and cells were fixed by adding 100 μl 
of 37% formaldehyde in culture media for 15 min at 37°C. Fixed cells were rinsed in 1 × 
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PBS and incubated with 300 ng/ml of DAPI for 15 min in 1 × PBS. Cells were rinsed three 
times in 1 × PBS, mounted in Permount (Fisher) and viewed with 40X/63X objective on a 
Leica DMIL inverted fluorescent microscope. The images were captured without software 
enhancement. The schematic representation of this experiment is given in Figure 1.
In Vitro Cytotoxicity of EFV Solution, CAP-EFV-NPs and CAP-EFV-NP-Gel
In vitro cytotoxicity of EFV solution, CAP-EFV-NPs and thermosensitive gel containing 
CAP-EFV-NPs (CAP-EFV-NP-Gel) was evaluated to establish ability of CAP nanoparticles 
to reduce cytotoxicity of efavirenz. Briefly, HeLa cells were seeded in 12 well plates at a 
density of 1 × 105 cells/well in triplicate and allowed to attach to wells overnight. EFV 
solution, CAP-EFV-NPs and CAP-EFV-NP-Gel were added to obtain EFV concentration of 
5 μg/ml in each well. Cell viability was assessed after 24, 48 and 96 h as per MTT method 
described in our earlier papers.25,26 HeLa cells grown in culture without any treatment 
served as control cells. The absorbance obtained for different treatment groups was 
compared to control cells (no treatment) to calculate% cell viability.
Short-Term In Vitro Prophylaxis of CAP Nanoparticles, EFV Solution and CAP-EFV-NPs
Short-term (1 day pre-treatment) in vitro prophylaxis of CAP nanoparticles, EFV solution 
and CAP-EFV-NPs against HIV-1NL4-3 was determined using TZM-bl HIV indicator cells as 
reported in our earlier publication.26 Briefly, TZM-bl cells were seeded in 96-well plates at a 
density of 1×104 cells per well. After 24 h, the cells were treated with different 
concentrations of CAP nanoparticles, EFV solution and CAP-EFV-NPs (concentration 
range: 50 μg/ml to 5 pg/ml). After 24 h, media from all the wells was removed to get rid of 
treatment and replaced with fresh media. On the following day, the cells were inoculated 
with HIV-1NL4-3 virus (25 μl) for 4 h. The cells were washed after the 4 h and incubated for 
48 h. Bright-GLO (Promega, Madison, WI) assay was used to measure the luminescence 
obtained with different treatments. TZM-bl cells with no treatment and HIV infection and 
HIV infected TZM-bl cells with no treatment were used as controls. The schematic 
representation of this experiment is given in Figure 1. The % antiviral activity was calculated 
using following formula
%antiviral activity = [(Luntreated − Ltreated)/Luntreated] × 100
where Luntreated is the luminescence of HIV infected TZM-bl cells with no treatment and 
Ltreated is the luminescence of HIV infected TZM-bl cells treated with CAP nanoparticles, 
EFV solution or CAP-EFV-NPs.
Short-Term In Vitro Prophylaxis of CAP Nanoparticles in Gel (CAP-NP-Gel) and CAP-EFV-
NP-Gel
Short-term in vitro experiment was repeated to study influence of thermosensitive gel and its 
components on the antiviral activity of CAP-EFV-NPs. The experimental design was similar 
to the earlier experiment. In this experiment, CAP nanoparticles incorporated into a gel and 
CAP-EFV-NP-Gel were used instead of CAP nanoparticles and CAP-EFV-NPs. Blank 
Pluronic gel was used as a control.
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Long-Term In Vitro Prophylaxis Using CAP Nanoparticles, EFV Solution and CAP-EFV-NPs
Long-term (3 days) in vitro prophylactic activity of CAP nanoparticles, EFV solution and 
CAP-EFV-NPs was evaluated using TZM-bl assay described earlier. Briefly, TZM-bl cells 
were seeded in 96-well plates at a density of 1 × 104 cells per well. After 24 h, the cells were 
treated with EFV solution and CAP-EFV-NPs (2 different batches) equivalent to 50 ng/ml 
and 5 ng/ml of EFV. After 24 h, media from all the wells was removed to get rid of treatment 
and replaced with fresh media. After 3 days, the cells were inoculated with HIV-1NL4-3 virus 
(25 μl) for 4 h. The rest of the procedure is similar to the earlier experiment. The schematic 
representation of this experiment is given in Figure 1.
Immunohistochemistry
TZM-bl cells were pre-treated with CAP-NP and CAP-EFV-NPs for 24 h and incubated with 
HIV-1NL4-3 for 4 h prior to washing and culturing for 48 h. For all nanoparticles, CAP was 
at concentration of 0.5, 5.0 and 50 μg/ml and EFV concentrations were 0.05, 0.5 and 5.0 
μg/ml. HeLa cells were fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) 
for 15 min at room temperature (RT) then washed with warm PBS. Cells were permeabilized 
with 0.2% Triton X-100 in PBS for 10 minutes, washed, and blocked for 1 hour at room 
temperature in PBS, 0.2% BSA, and 0.2% Triton X-100. Cells were incubated with primary 
antibody directed against β-galactosidase (Thermo Fisher, 1:1000) overnight at 4°C in PBS, 
0.2% BSA, and 0.2% Triton X-100. Cells were washed in PBS and secondary antibodies 
were applied at a concentration of 1:500 for 1 h at room temperature for goat anti-rabbit IgG 
(H+L) rhodamine conjugate. Qualitative and quantitative analysis of immunocytochemistry 
was performed by acquiring images with a Leica DMI4000B inverted microscope with a 
cooled CCD camera (Q Imaging) and fluorescent capabilities. Images were analyzed with 
ImageProPlus software (MediaCybernetics). For image data, 3 field views of at least 100 
cells from 3 separate experiments were analyzed for each condition.
Statistical Analysis
Results are reported as mean + SEM for all experiments. Statistical significance was 
evaluated using Student’s t-test or analysis of variance (ANOVA, GraphPad Prism). 
Differences were considered statistically significant at p < 0.05.
RESULTS
Preparation of Blank CAP Nanoparticles
For preparation of CAP nanoparticles, various biocompatible non-ionic surfactants such as 
Tween 80, Tween 20, Solutol HS 15, Myrj 52, Vitamin E TPGS, Pluronic F68 and Pluronic 
F127 were evaluated. These surfactants have different chemical structures and HLB values. 
Particle size and polydispersity index of CAP nanoparticles stabilized by various surfactants 
are shown in Figure 2. All surfactants were able to form CAP nanoparticles with size less 
than 150 nm. Pluronic F127 showed lowest particle size and polydispersity index amongst 
all the surfactants. Moreover, CAP nanoparticles stabilized with Tween 80, Tween 20, 
Solutol HS 15, Myrj 52 and Vitamin E TPGS showed signs of colloidal instability after 24 h 
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whereas Pluronic stabilized CAP nanoparticles exhibited good colloidal stability. Pluronic 
F127 stabilized CAP nanoparticles were selected for further studies.
In Vitro Cytotoxicity of CAP Nanoparticles
Cytotoxicity of CAP nanoparticles to HeLa cells was evaluated using MTT method. CAP 
nanoparticles did not show signs of cytotoxicity to HeLa cells even at a concentration 
equivalent to 500 μg/ml of CAP after 48 h (Fig. 3). These observations are in accordance 
with the in vitro cytotoxicity data reported for CAP.27
Preparation and Characterization of EFV Loaded CAP Nanoparticles (CAP-EFV-NPs)
EFV could be successfully incorporated into CAP nanoparticles. No drug precipitation or 
nanoparticle aggregation was observed after incorporation of EFV into CAP nanoparticles 
after 24 h. The particle size, polydispersity index and zeta potential of CAP-EFV-NPs are 
listed in Table I. The encapsulation efficiency of EFV in CAP nanoparticles was greater than 
98% (Table I). SEM image showed that CAP-EFV-NPs were spherical and less than 100 nm 
(Fig. 4).
Development of a Thermosensitive Vaginal Gel Containing CAP-EFV-NPs (CAP-EFV-NP-
Gel)
A thermosensitive vaginal gel containing CAP-EFV-NPs was developed using a mixture of 
Pluronic F127 (20% w/v) and Pluronic F68 (1% w/v). Incorporation of CAP-EFV-NPs into a 
thermosensitive gel did not show any visible signs of aggregation of CAP-EFV-NPs after 48 
h at room temperature.
Characterization of Transfer of Fluorescent CAP Nanoparticles from Thermosensitive Gel 
Using Transwell® Permeable Supports
We wanted to have an estimate of duration required by the thermosensitive gel to enable 
release (or translocation) of CAP nanoparticles. Hence, thermosensitive gel containing 
fluorescent CAP nanoparticles was placed on 0.2 μm Transwell® permeable supports and 
allowed to solidify at 37°C. We hypothesized that CAP nanoparticles released from the gel 
would translocate through the Transwell® membrane and be taken up by HeLa cells cultured 
below the permeable support. The results of these experiments are shown in Figure 5. 
Fluorescent nanoparticles were able to transfer through Transwell® permeable supports and 
were taken up by HeLa cells within 30 min. Rhodamine fluorescence intensity in the cells 
grew stronger until 24 h and slowly diminished over a sustained time frame. Rhodamine 
fluorescence could be observed in HeLa cells even after 4 days (Fig. 5).
In Vitro Cytotoxicity of EFV Solution, CAP-EFV-NPs and CAP-EFV-NP-Gel
In vitro cytotoxicity of EFV solution, CAP-EFV-NPs and CAP-EFV-NP-Gel to HeLa was 
evaluated to check whether nanoparticles can reduce the cytotoxicity of efavirenz. CAP-
EFV-NPs and CAP-EFV-NP-Gel showed significantly higher cell viability (P < 0.01) as 
compared to EFV solution at 48 h and 96 h (Fig. 6). This clearly indicated the advantage of 
CAP-EFV-NPs and CAP-EFV-NPs in thermosensitive gel.
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Short-Term In Vitro Prophylaxis of CAP Nanoparticles, EFV Solution and CAP-EFV-NPs
To evaluate whether combination of CAP and EFV in the form of nanoparticles provide 
enhanced prophylactic activity, short-term in vitro prophylaxis experiments were carried out 
as per our earlier report.26 CAP-EFV-NPs showed significantly higher anti-HIV activity (P < 
0.01) as compared to EFV solution at concentrations ≤50 ng/ml by significantly reducing 
HIV infection in pretreated TZM-bl indicator cells (Fig. 6). Interestingly, CAP-EFV-NPs 
showed more than 50% antiviral activity even at a concentration equivalent to 500 pg/ml of 
EFV whereas EFV solution did not show any inhibition at this concentration. CAP 
nanoparticles showed antiviral activity at concentration of 50 μg/ml confirming previous 
reports demonstrating anti-HIV activity of CAP.27 However, CAP nanoparticles showed 
negligible antiviral activity at concentrations ≤ 5 μg/ml (Fig. 7). CAP-EFV-NPs showed 
significantly higher anti-HIV activity (P < 0.01) as compared to CAP nanoparticles at all 
concentrations ≤ 5 μg/ml. This study clearly demonstrated the advantage of CAP-EFV-NPs 
over CAP nanoparticles as well as EFV solution for prophylaxis.
Short-Term In Vitro Prophylaxis of CAP-NP-Gel and CAP-EFV-NP-Gel
Short-term in vitro prophylaxis experiment was also performed using CAP nanoparticles in 
gel and CAP-EFV-NP-Gel. Blank Pluronic gel served as a control. CAP-EFV-NP-Gel 
showed significantly higher anti-HIV activity at all concentrations starting from 5 μg/ml 
(Fig. 8). Blank gel showed negligible anti-HIV activity at all concentrations. CAP-EFV-NP-
Gel showed similar anti-HIV activity profile as that of CAP-EFV-NP. This indicated that 
components of gel did not have any positive or negative effect on anti-HIV activity of CAP-
EFV-NPs.
Long-Term In Vitro Prophylaxis Using CAP Nanoparticles, EFV Solution and CAP-EFV-NPs
Long-term in vitro HIV prophylaxis experiments were performed to ascertain whether 
combination of CAP and EFV in the form of nanoparticles can prevent HIV infection for 3 
days after 1 day pre-treatment of TZM-bl cells with CAP nanoparticles, CAP-EFV-NPs and 
EFV solution. CAP-EFV-NPs and EFV solution equivalent to 50 ng/ml and 5 ng/ml of EFV 
were selected for this study. At a concentration equivalent to 50 ng/ml of EFV, CAP-EFV-
NPs as well as EFV solution did not show any significant difference in anti-HIV activity 
(Fig. 9). However, CAP-EFV-NPs showed significantly higher antiviral activity (P < 0.01) as 
compared to EFV solution at a concentration equivalent to 5 ng/ml of EFV (Fig. 9). CAP 
nanoparticles were used as a control to account for anti-HIV activity of CAP in CAP-EFV-
NPs. CAP nanoparticles showed significantly lower anti-HIV activity as compared to CAP-
EFV-NPs.
Immunohistochemistry
Immunohistochemistry was performed to validate results of in vitro prophylaxis experiments 
using TZM-bl cells. TZM-bl cells contain a β-galactosidase promoter which is activated 
upon HIV infection. We evaluated β-galactosidase expression in HIV infected TZM-bl cells 
with no treatment, TZM-bl cells treated with CAP nanoparticles and TZM-bl cells treated 
with CAP-EFV-NPs by using antibody against β-galactosidase. HIV infected TZM-bl cells 
with no treatment showed considerable β-galactosidase expression as indicated by the 
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presence of red fluorescence in the cells (Fig. 10). TZM-bl cells treated with CAP 
nanoparticles showed negligible red fluorescence indicating little β-galactosidase expression 
at a concentration of 50 μg/ml. β-galactosidase immunofluorescence was higher at lower 
concentrations of CAP nanoparticles (5 μg/ml and 0.5 μg/ml). Cells incubated with CAP-
EFV-NPs did not express β-galactosidase at all concentrations tested and are unlikely to be 
infected with HIV as indicated by undetectable levels of β-galactosidase 
immunofluorescence. This study validated results of in vitro prophylaxis experiments. We 
also counted at least 100 cells from 3 different locations to determine number of β-
galactosidase+ cells and calculated% infection in untreated, CAP NP treated and CAP-EFV-
NP treated cells (Table II).
DISCUSSION
Development of various modalities for prevention of HIV has received a great impetus in 
recent years. As sexual transmission is the most common mode of HIV infection, strategies 
to prevent/inhibit HIV at its route of entry (vaginal or rectal) are considered to be important 
for HIV prophylaxis. In view of this, vaginal or rectal delivery of natural or semi-synthetic 
polymers and antiretroviral agents has been attempted for HIV prophylaxis.5,21 Although 
many natural or semi-synthetic polymers can act as HIV-1 entry inhibitors, they were not 
successful in clinical trials.6 Moreover, vaginal delivery of antiretroviral agents like 
tenofovir has also shown a moderate success in HIV prevention.7 Hence, novel approaches 
are required for improving HIV prophylaxis. Nanotechnology has the potential to bring a 
paradigm shift in the field of HIV prophylaxis and a nanotechnology-based product is 
already being evaluated in clinical trials for HIV prophylaxis.
In the present investigation, we aimed at developing a nano-microbicide containing a 
combination of HIV-1 entry inhibitor (cellulose acetate phthalate; CAP) and NNRTI 
(efavirenz) for establishing the proof-of-concept. CAP is a FDA approved semi-synthetic 
cellulose.11 Due to its pH sensitive nature, CAP is commonly used for enteric coating of 
tablets to prevent drug release in acidic environment of stomach. Interestingly, CAP also acts 
as a HIV-1 entry inhibitor in soluble as well as insoluble form.16 Safety of CAP for vaginal 
delivery and its efficacy in preventing HIV infection (in macaques) has been proven.17–19 
Additionally, low-cost and ease of availability of CAP are also important criteria for its 
application as a modality for HIV prevention. Efavirenz is a FDA-approved potent NNRTI 
with longer half-life and maximum stability at vaginal pH.28,29 Our earlier studies indicate 
that nano-encapsulated efavirenz can reside in cells for as long as 14 days which indicated 
that efavirenz may have potential for long-term HIV prophylaxis.26 In this investigation, we 
used CAP nanoparticles as a modality for HIV prophylaxis as well as a modality to deliver 
efavirenz. Until today, there are very few reports on the development of CAP nanoparticles.
30,31
 These investigations employ polyvinyl alcohol as a stabilizer for CAP nanoparticles. 
However, it has been shown that polyvinyl alcohol stabilized nanoparticles are trapped in the 
cervicovaginal mucus and will not reach vaginal epithelium (which are one of the main 
target cells for HIV prophylaxis).32 Hence, we screened various FDA approved non-ionic 
surfactants for fabrication of CAP nanoparticles. We employed simple, low energy and 
scalable nanoprecipitation method for fabrication of CAP nanoparticles. Various nonionic 
surfactants such as Tween 80, Tween 20, Solutol HS 15, Myrj 52, Vitamin E TPGS (or 
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Kolliphor TPGS), Pluronic F68 and Pluronic F127 were screened for fabrication of CAP 
nanoparticles with good colloidal stability. Interestingly, CAP nanoparticle stabilized with 
Pluronic F127 showed lowest particle size and good colloidal stability (Fig. 2). It was also 
observed that concentration of Pluronic F127 and ratio of organic solvent to aqueous phase 
had considerable effect on the size and colloidal stability of the nanoparticles (data not 
shown). CAP nanoparticles stabilized with 2% Pluronic F127 had size less than 100 nm and 
good colloidal stability (Table I). It has been demonstrated that Pluronic F127 stabilized 
nanoparticles can rapidly penetrate through cervicovaginal mucus and can reach vaginal 
epithelium.32,33 Hence, Pluronic F127 stabilized CAP nanoparticles were selected for the 
further studies. Although in vitro and in vivo safety of CAP has been demonstrated, we 
wanted to assess effect of nano-scale CAP on cell viability. CAP nanoparticles did not show 
any signs of cytotoxicity in HeLa cells at a concentration of 500 μg/ml after 48 h indicating 
a good safety profile (Fig. 4). Efavirenz could be incorporated into CAP nanoparticles with 
high encapsulation efficiency (encapsulation efficiency: > 98% and drug loading: ~10% w/w 
of CAP). Encapsulation of efavirenz had negligible effect on the size of CAP nanoparticles. 
CAP-EFV nanoparticles were incorporated into the thermosensitive gel reported in our 
earlier publication.26 Incorporation of CAP-EFV nanoparticles did not have any effect on the 
colloidal stability of nanoparticles and thermogelation temperature of gel. Although we have 
shown in our earlier publication that thermosensitive gel allows rapid translocation (< 30 
min) of PLGA nanoparticles26, we wanted to ensure that CAP nanoparticles can also rapidly 
translocate through the thermosensitive gel. Furthermore, we also wanted to monitor 
residence time of the CAP nanoparticles in the HeLa cells after translocation through 
transwell membrane. We did not carry out this study in our earlier investigation. We 
hypothesized that if the fluorescently labeled CAP nanoparticles can remain in the HeLa 
cells for longer duration, then it might be possible to achieve long-term prophylaxis. 
Interestingly, CAP nanoparticles showed fluorescence in HeLa cells up to 4 days (Fig. 5).
The ability of CAP nanoparticles to improve selectivity index of efavirenz was evaluated by 
monitoring cytotoxicity of efavirenz, CAP-EFV NPs and CAP-EFV-NP gel to HeLa cells 
over a period of 4 days. Based on our earlier publication,26 we selected EFV concentration 
of 5 μg/ml for cytotoxicity studies. We also used 2 different batches of CAP-EFV-NPs and 
CAP-EFV-NP gel in order to evaluate whether there is batch-to-batch variation in results. 
Interestingly, both batches of CAP-EFV-NPs and CAP-EFV-NP gel were significantly less 
toxic to HeLa cells (P < 0.01) than EFV solution after 48 and 96 h of treatment (Fig. 6) and 
there was negligible batch to batch variation. Encapsulation of EFV into CAP nanoparticles 
may reduce its interaction with cell organelles such as mitochondria which can ultimately 
lead to reduced cytotoxicity. Thus, CAP nanoparticles can improve selectivity index of 
efavirenz. These results also established that the components of thermosensitive gel did not 
have any cytotoxic effect on the cells. The antiviral efficacy of various concentrations of 
CAP nanoparticles, CAP-EFV-NPs and EFV solution (concentration range: 50 μg/ml to 5 
pg/ml) was determined using a modified protocol that mimics prophylaxis. We also wanted 
to evaluate whether delivering a combination of CAP and EFV in the form of nanoparticles 
has any advantage over individual treatments. It should be noted that EFV solution and 
CAP-EFV-NPs were not studied at a concentration of 50 μg/ml because of the cytotoxicity 
issues. In order to establish that concentrations < 50 μg/ml are non-toxic to cells, we 
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evaluated cytotoxicity of CAP-EFV-NPs from concentration of 5 μg/ml to 5 pg/ml using 
CellTiterGLO™ assay. We observed that the selected concentrations are non-toxic to cells. 
Hence, the reduction in the luminescence (corresponding to % antiviral activity) was not due 
to the cytotoxicity. It is evident that CAP nanoparticles showed considerable antiviral 
efficacy only at the concentration of 50 μg/ml (Fig. 7) and at lower concentrations the 
antiviral activity of CAP nanoparticles was negligible. EFV solution showed considerable 
antiviral activity (more than 50%) up to concentration of 50 ng/ml whereas CAP-EFV-NPs 
showed more than 50% antiviral activity even at the concentration of 500 pg/ml (Fig. 7). It is 
noteworthy that CAP-EFV-NPs showed significantly higher antiviral activity (P < 0.01) as 
compared to EFV solution at all the concentrations after 50 ng/ml. This clearly indicated the 
advantage of delivering a combination of CAP and EFV as nanoparticles. The dramatically 
higher antiviral activity of CAP-EFV-NPs as compared to CAP nanoparticles and EFV 
solution alone also indicated the possibility of synergistic interaction between CAP and 
EFV. Further, we evaluated concentration dependent antiviral activity of CAP nanoparticles 
and CAP-EFV-NPs after their incorporation into the thermosensitive gel. We also evaluated 
thermosensitive gel alone for antiviral activity. Interestingly, antiviral activity of CAP 
nanoparticles and CAP-EFVNPs did not change even after incorporation into 
thermosensitive gel (Fig. 8). Moreover, blank gel did not show any antiviral activity (Fig. 8). 
Thus, thermosensitive gel had neither positive nor negative effect on the antiviral activity of 
CAP-EFV-NPs.
In order to establish the potential of CAP-EFV-NPs for the long-term HIV prophylaxis, we 
further modified the antiviral efficacy protocol. For this purpose, we pre-treated TZM-bl 
cells for 1 day with EFV solution, CAP-EFV-NPs (equivalent to 50 ng/ml and 5 ng/ml of 
EFV) or CAP nanoparticles (at CAP concentrations equivalent to that present in CAP-EFV-
NPs) and all the samples were infected with HIV-1 after 3 days of EFV solution, CAP-EFV-
NPs and CAP nanoparticles pre-treatment of TZM-bl cells. We also evaluated two different 
batches of all the samples to confirm batch-to-batch reproducibility of the results. 
Interestingly, CAP-EFV-NPs showed significantly higher (P < 0.01) antiviral activity only at 
a concentration equivalent to 5 ng/ml of EFV (Fig. 9). The lack of difference in antiviral 
activity between EFV solution and CAP-EFV-NPs at a concentration of 50 ng/ml indicates 
that EFV (even as a free drug) can reside inside HeLa cells for a longer duration. It is known 
that HeLa cells do not express CYP450 enzymes required for efavirenz metabolism.34 As 
TZM-bl cells are engineered from HeLa cells, they are unlikely to have these CYP450 
enzymes. This could be the reason for longer residence of efavirenz in the TZM-bl cells. It is 
reported that the EC90 value of EFV (free drug) is around 0.1–1.6 ng/ml.35,36 If EFV (as a 
free drug) can reside in the TZM-bl cells for a longer duration then pre-treatment of cells 
with EFV solution with a concentration of 50 ng/ml (almost 50-fold higher than EC90 may 
still maintain a concentration greater than EC90 value of efavirenz in the cells even after 3 
days. In such a situation, EFV solution and CAP-EFV-NPs will show similar antiviral 
activity. Due to limitations of our HPLC assay, we could not determine whether pre-
treatment of TZM-bl cells with 50 ng/ml of EFV solution yield measurable intracellular 
concentrations of EFV for 3 days. Nevertheless, pre-treatment of cells with a 10-fold lower 
concentration of EFV showed superiority of CAP-EFV-NPs. Finally, we also validated the 
functionality of in vitro HIV prophylaxis experiments by immunohistochemistry studies. β-
Date et al. Page 12
J Biomed Nanotechnol. Author manuscript; available in PMC 2018 June 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
galactosidase expression assays demonstrated that 24 hour pre-treatment with CAP-EFV-
NPs completely inhibits HIV-1 infection of TZM-bl indicator cells for 96 hours following 
exposure to HIV-1 (Fig. 10). Quantitative evaluation was done by measuring β-galactosidase 
+ cells to determine level of HIV infection in the different treatments. It was observed that 
none of the cells treated with CAP-EFV-NPs showed HIV infection indicating a good 
correlation was observed between qualitative and quantitative analysis.
Recently, Huang et al., have reported potential of CAP nanofibers either alone or in 
combination with for antiretroviral drugs (TMC 125 and tenofovir) for HIV prophylaxis by 
in vitro studies.37 Although the results were promising, Huang et al., performed short term 
(1 h) HIV neutralization studies which involved incubation of CAP nanofibers with or 
without tenofovir with HIV-1. Huang et al., noted that CAP nanofibers have synergistic 
effect with antiretroviral drugs (which corroborate our results with CAP-EFV-NPs). Our 
investigation is quite different from Huang et al., as we focused on a different nano-
architecture (nanoparticles instead of nanofibers) and different delivery vehicle 
(thermosensitive gel). Moreover, we focused on short-term and long-term pre-treatment of 
cells with CAP nanoparticles and CAP-EFV-NPs followed by HIV-1 infection as it mimics 
clinical situation and also gives some hint about long-term HIV prophylaxis.
CONCLUSION
Cellulose acetate phthalate nanoparticles can be used as a modality for HIV prevention and 
for delivering antiretroviral drugs such as efavirenz. Cellulose acetate phthalate-efavirenz 
combination nanoparticles showed significantly higher antiviral activity and significantly 
less cytotoxicity as compared to efavirenz alone. In vitro studies suggest that CAP-EFV-NPs 
can have potential for long-term HIV prophylaxis and thermosensitive gel containing CAP-
EFV-NPs could be a clinically viable nano-scale modality for HIV prophylaxis. Further 
studies will be focused on establishing in vivo proof of long-term HIV prophylaxis using 
humanized BLT mouse model for HIV-1 infection.
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Figure 1. 
Schematic representation of thranslocation through transwell permeable support experiment 
and in vitro short-term and long-term prophylaxis experiments.
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Figure 2. 
Effect of various nonionic surfactants on the particle size of CAP nanoparticles (n = 3); T20: 
Tween 20, T80: Tween 80, SHS 15: Solutol HS 15, TPGS: Vitamin E TPGS, M52: Myrj 52, 
F68: Pluronic F68, F127: Pluronic F127.
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Figure 3. 
In vitro cytotoxicity of CAP nanoparticles to HeLa cells (n = 6).
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Figure 4. 
SEM image of CAP-EFV-NPs.
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Figure 5. 
Time dependent fate of Rhodamine-6G labeled CAP nanoparticles (embedded in 
thermosensitive gel) in HeLa cells after translocation through transwell permeable supports 
(n = 3).
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Figure 6. 
In vitro cytotoxicity of EFV solution, blank gel, CAP-EFV-NPs and CAP-EFV-NP-Gel to 
HeLa cells (n = 6); ∗∗P < 0.01; B1 and B2: Batch 1 and Batch 2; CAP-EFV-NP: Cellulose 
acetate phthalate combination nanoparticles; CAP-EFV-NP-Gel: Thermosensitive gel 
containing CAP-EFV-NPs; EFV concentration in EFV solution, CAP-FEV-NPs (both 
batches) and CAP-FEV-NP-Gel (both batches) was 5 μg/ml.
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Figure 7. 
Results of in vitro short-term HIV prophylaxis study of CAP nanoparticles, EFV solution 
and CAP-EFV-NPs (n = 6).
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Figure 8. 
Results of short-term in vitro prophylaxis study of thermosensitive gel containing CAP 
nanoparticles or CAP-EFV-NPs (n = 6).
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Figure 9. 
Results of long-term in vitro HIV prophylaxis study (n = 6); ∗∗P < 0.01; B1 and B2: Batch 1 
and Batch 2; CAP-NP: Cellulose acetate phthalate nanoparticles; CAP-EFV-NP: Cellulose 
acetate phthalate combination nanoparticles; EFV-50 ng/ml: Solution containing 50 ng/ml of 
EFV; EFV-5 ng/ml: Solution containing 5 ng/ml of EFV.
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Figure 10. 
β-galactosidase expression in TZM-bl cells treated with CAP nanoparticles or CAP-EFV 
NPs; Red color indicates β-galactosidase + HIV infected cells and blue color indicates β-
galactosidase negative cells (no HIV infection); CAP-NP-0.5: NPs with 0.5 μg/ml of CAP; 
CAP-NP-5: NPs with 5 μg/ml of CAP; CAP-NP-50: NPs with 50 μg/ml of CAP; CAP-EFV-
NP-0.5: NPs with 5 μg/ml of CAP and 50 ng/ml of EFV; CAP-EFV-NP-5: NPs with 5 μg/ml 
of CAP and 0.5 μg/ml of EFV; CAP-EFV-NP-50: NPs with 50 μg/ml of CAP and 5 μg/ml of 
EFV.
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Table I
Physicochemical characteristics of CAP nanoparticles and CAP-EFV-NPs.
Parameter CAP Nanoparticles CAP-EFV-NPs
Particle size 82 2 ± 4 7 nm 96 9 ± 11 3 nm
Polydispersity index 0.16 ± 0.02 0.17 ± 0.02
Zeta potential −22 47 ± 5 5 mV −17.08 ± 2.68 m
Encapsulation efficiency of EFV – 98.1 ± 1.2%
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